BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abutaleb A, Sherman KE. A changing paradigm: management and treatment of the HCV/HIV-co-infected patient. Hepatol Int 2018;12:500-9. [PMID: 30238230 DOI: 10.1007/s12072-018-9896-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Medrano LM, Berenguer J, Salgüero S, González-García J, Díez C, Hontañón V, Garcia-Broncano P, Ibañez-Samaniego L, Bellón JM, Jiménez-Sousa MA, Resino S. Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study. Front Med (Lausanne) 2021;8:615342. [PMID: 33598470 DOI: 10.3389/fmed.2021.615342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Salgüero S, Rojo D, Berenguer J, González-García J, Fernández-Rodríguez A, Brochado-Kith O, Díez C, Hontañon V, Virseda-Berdices A, Martínez J, Ibañez-Samaniego L, Llop-Herrera E, Barbas C, Resino S, Jiménez-Sousa MA; Escorial Study Group. Plasma metabolomic fingerprint of advanced cirrhosis stages among HIV/HCV-coinfected and HCV-monoinfected patients. Liver Int 2020;40:2215-27. [PMID: 32593189 DOI: 10.1111/liv.14580] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Carrasco I, Sainz T, Frick MA, Jiménez de Ory S, Fortuny C, Burgos J, Montero M, Gavilán C, Falcón MD, Couceiro JA, Bernardino JI, Bisbal O, Guerrero C, Aldámiz-Echevarría MT, Berenguer J, Navarro ML; the Pediatric National AIDS Research Network of Spain (CoRISpe) integrated in the Translational Research Network in Pediatric Infectious Diseases (RITIP). Response to direct-acting antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients. J Viral Hepat 2020;27:955-8. [PMID: 32347645 DOI: 10.1111/jvh.13308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Schwerk J, Negash A, Savan R, Gale M Jr. Innate Immunity in Hepatitis C Virus Infection. Cold Spring Harb Perspect Med 2021;11:a036988. [PMID: 32341066 DOI: 10.1101/cshperspect.a036988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 De Pablo-Bernal RS, Jimenez-Leon MR, Tarancon-Diez L, Gutierrez-Valencia A, Serna-Gallego A, Trujillo-Rodriguez M, Alvarez-Rios AI, Milanes-Guisado Y, Espinosa N, Roca-Oporto C, Viciana P, Lopez-Cortes LF, Ruiz-Mateos E. Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus. Antimicrob Agents Chemother 2020;64:e00773-20. [PMID: 32571815 DOI: 10.1128/AAC.00773-20] [Reference Citation Analysis]
6 Piekarska A, Jabłonowska E, Garlicki A, Sitko M, Mazur W, Jaroszewicz J, Czauz-Andrzejuk A, Buczyńska I, Simon K, Lorenc B, Dybowska D, Halota W, Pawłowska M, Dobracka B, Berak H, Horban A, Tudrujek-Zdunek M, Tomasiewicz K, Janczewska E, Socha Ł, Laurans Ł, Parczewski M, Zarębska-Michaluk D, Pabjan P, Belica-Wdowik T, Baka-Ćwierz B, Deroń Z, Krygier R, Klapaczyński J, Citko J, Berkan-Kawińska A, Flisiak R. Real life results of direct acting antiviral therapy for HCV infection in HIV-HCV-coinfected patients: Epi-Ter2 study. AIDS Care 2020;32:762-9. [PMID: 31345052 DOI: 10.1080/09540121.2019.1645808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
7 Oikonomou KG, Tsai E, Sarpel D, Dieterich DT. Liver Disease in Human Immunodeficiency Virus Infection. Clin Liver Dis 2019;23:309-29. [PMID: 30947879 DOI: 10.1016/j.cld.2018.12.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis]
9 Patel SV, Jayaweera DT, Althoff KN, Eron JJ, Radtchenko J, Mills A, Moyle G, Santiago S, Sax PE, Gillman J, Mounzer K, Elion RA, Huhn GD. Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCV. PLoS One 2020;15:e0228847. [PMID: 32053682 DOI: 10.1371/journal.pone.0228847] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
10 Yunihastuti E, Amelia F, Hapsari AI, Wicaksana B, Natali V, Widhani A, Sulaiman AS, Karjadi TH. Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus. Health Qual Life Outcomes 2021;19:154. [PMID: 34039353 DOI: 10.1186/s12955-021-01777-x] [Reference Citation Analysis]
11 Salgüero S, Medrano LM, González-García J, Berenguer J, Montes ML, Diéz C, Garcia-Broncano P, Llop-Herrera E, Pérez-Latorre L, Bellóno JM, Jiménez-Sousa MÁ, Resino S. Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study. Sci Rep 2020;10:10384. [PMID: 32587340 DOI: 10.1038/s41598-020-67159-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]